Esposito Emanuela, Avino Franca, di Giacomo Raimondo, Donzelli Ivana, Marone Ugo, Melucci Maria Teresa, Rinaldo Chiara, Ruffolo Fulvio, Saponara Ruggero, Siani Claudio, Tortoriello Raffaele, Botti Gerardo, Rinaldo Massimo, Fucito Alfredo
Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Naples, Italy.
Department of Clinical Medicine and Surgery, University of Naples, Federico II, Naples, Italy.
Transl Cancer Res. 2019 Oct;8(Suppl 5):S510-S517. doi: 10.21037/tcr.2019.07.38.
Angiosarcoma of the breast is one of the rarest malignancies. Breast angiosarcoma can be classified into primary when arising de novo and secondary to chronic lymphoedema or breast irradiation. Molecular pathways involved in angiosarcoma development have not been described clearly, yet some gene point mutations and protein altered expression levels have been detected. So far, their management is based above all on surgery. Hence, further studies starting from the few known key points may help to develop more effective strategies based both on target therapies, together with surgery.
乳腺血管肉瘤是最罕见的恶性肿瘤之一。乳腺血管肉瘤可分为原发性(即新发)和继发于慢性淋巴水肿或乳腺放疗后的继发性。血管肉瘤发生发展所涉及的分子途径尚未明确描述,但已检测到一些基因点突变和蛋白质表达水平改变。到目前为止,其治疗主要基于手术。因此,从少数已知关键点出发进行进一步研究,可能有助于开发出基于靶向治疗与手术相结合的更有效策略。